|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Partially hydrolyzed guar gum in pediatric functional abdominal pain显示文摘AIM:To assess the effects of partially hydrolyzed guar gum(PHGG) diet supplement in pediatric chronic abdominal pain(CAP) and irritable bowel syndrome(IBS).METHODS:A randomized,double-blind pilot study was performed in sixty children(8-16 years) with functional bowel disorders,such as CAP or IBS,diagnosed according to Rome Ⅲ criteria.All patients underwent ultrasound,blood and stool examinations to rule out any organic disease.Patients were allocated to receive PHGG at dosage of 5 g/d(n = 30) or placebo(fruitjuice n = 30) for 4 wk.The evaluation of the efficacy of fiber supplement included IBS symptom severity score(Birmingham IBS Questionnaire),severity of abdominal pain(Wong-Baker Face Pain Rating Score) and bowel habit(Bristol Stool Scale).Symptom scores were completed at 2,4,and 8 wk.The change from baseline in the symptom severity scale at the end of treatment and at 4 wk follow-up after treatment was the primary endpoint.The secondary endpoint was to evaluate compliance to supplementation with the PHGG in the pediatric population.Differences within groups during the treatment period and follow-up were evaluated by the Wilcoxon signed-rank test.RESULTS:The results of the study were assessed considering some variables,such as frequency and intensity of symptoms with modifications of the bowel habit.Both groups were balanced for baseline characteristics and all patients completed the study.Group A(PHGG group) presented a higher level of efficacy compared to group B(control group),(43% vs 5%,P = 0.025) in reducing clinical symptoms with modification of Birmingham IBS score(median 0 ± 1 vs 4 ± 1,P = 0.025),in intensity of CAP assessed with the Wong-Baker Face Pain Rating Score and in normalization of bowel habit evaluated with the Bristol Stool Scale(40% vs 13.3%,P = 0.025).In IBS subgroups,statistical analysis shown a tendency toward normalization of bowel movements,but there was no difference in the prevalence of improvement in two bowel habit subsets.PHGG was therefore better tolerated without any adverse effects.CONCLUSION:Although the cause of pediatric functional gastrointestinal disorders is not known,the results show that complementary therapy with PHGG may have beneficial effects on symptom control. | Claudio Romano Donatella Comito Annalisa Famiani Sabrina Calamarà Italia Loddo | 2013 | World Journal of Gastroenterology2013，19，2： | 3 |
| 2 | Measurement of runoff and soil erosion in three areas under different land use in Sardinia( Italy) 显示文摘 | Vacca A Loddo S Ollesch G | 2000 | Catena2000，40，： | 1 |
| 3 | DNA replication licensing factors and aneuploidy are linked to tumor cell cycle state and clinical outcome in penile carcinoma显示文摘 | Kayes O J Loddo M Patel N | 2009 | Clin Cancer Res2009，15，23： | 1 |
| 4 | Gemcitabine plus cisplatin in the treatment of patients with advanced non-sinai cell lung cancer: a phase I study显示文摘 | Bretti S Manzin E Loddo C | 2002 | Anticancer Res2002，2，5： | 1 |
| 5 | MCM2, Geminin, and Ki67 define proliferative state and are prognostic markers in renal cell carcinoma 显示文摘 | Dudderidge TJ Stoeber K Loddo M | 2005 | Clin Cancer Res2005，11，7： | 1 |
| 6 | Heterogeneous photocatalytic degradation of pharmaceuticals in water by using polycrystalline TiO2 and a nanofiltration membrane reactor 显示文摘 | MOLINARI R PIRILLO F LODDO V | 2006 | Catalysis Today2006，118，12： | 1 |
| 7 | Photodegradation of lincomycin in aqueous solution显示文摘 | Di Paola A Addamo M Augugliaro V García-López E Loddo V Marcì G Palmisano L | | 0，，： | 1 |
| 8 | Multimodal management of stages III–IVa malignant thymoma显示文摘 | S Bretti A Berruti C Loddo P Sperone C Casadio M Tessa F Ardissone G Gorzegno M Sacco E Manzin P Borasio G.L Sannazzari G Maggi L Dogliotti | 2003 | Lung Cancer2003，，1： | 1 |
| 9 | Heterogeneous photocatalytic degradation of pharmaceuticals in water by using polycrystalline TiO2 and a nanofiltration membrane reactor 显示文摘 | Molinari R Pirillo F Loddo V | 2006 | Cataly Today2006，118，： | 1 |
| 10 | Gemcitabine plus cisplatin in the treatment of patients with advanced non- smal cell lung cancer: a phase I study 显示文摘 | Bretti S Manzin E Loddo C | 2002 | Anticancer Res2002，2，5： | 1 |
| 11 | Serum levels of interleukin 1 beta,interleukin 8 and turnout necrosis factor alpha as markers of gastric cancer显示文摘 | Macri A Versaci A Loddo S | 2006 | Biomarkers2006，11，2： | 1 |
| 12 | Gemcitabine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a phase Ⅱ study显示文摘 | Bretti S Manzin E Loddo C | 2002 | Anticancer Res2002，22，5： | 1 |
| 13 | Degradation of lincomycin in aqueous medium:coupling of solar photocatalysis and membrane separation显示文摘 | Augugliaro V Garcia-Lopez E Loddo V | 2005 | Solar Energy2005，79，4： | 1 |
| 14 | Transponder calibration of the Envisat RA-2 altimeter Ku band sigma naught显示文摘 | N. Pierdicca C. Bignami M. Roca P. Féménias M. Fascetti M. Mazzetta C.N. Loddo A. Martini S. Pinori | 2012 | Advances in Space Research2012，，： | 1 |
| 15 | Gemcitabine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer:a phase Ⅱ study显示文摘 | Manzin E Loddo C | 2002 | Anticancer Res2002，22，5： | 1 |
| 16 | 显示文摘 | Augugliaro V Kisch H Loddo V | 2008 | Applied Catalysis A2008，349，： | 1 |
| 17 | The First Terrestrial Laser Scanner Survey over Vesuvius:the High Resolution Model of Volcano Crater显示文摘 | PESGI A LODDO F C0NF0RTI D | 2007 | International Journal of Re- mote Sensing2007，28，1： | 1 |
| 18 | Modeling Weed emergence in Italian maize fields显示文摘 | Masin R Loddo D Benvenuti S | 2012 | Weed Science2012，60，2： | 1 |
| 19 | Photocatalytic oxidation of gaseous toluene on anatase TiO2 catalyst:mechanistic aspects and FT-IR investigation 显示文摘 | Coluccia S Loddo V | 1999 | Appl Catal B:Environ1999，20，： | 1 |
| 20 | Detectioned benign intracavitary lesions in postmenopausal women with abnormal uterine bleeding:a prospective comparative study on outpatient hysteroscopy and blind biopsy显示文摘 | Angioni S Loddo A Milano F | 2008 | J Minimally Invasive Gynecol2008，15，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员